Company news

Amylyx Pharmaceuticals, Inc. news in 2025

Amylyx Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial

December 4, 2025

Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results

November 5, 2025

Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences

November 2, 2025

Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

October 29, 2025

Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock

September 9, 2025

Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock

September 8, 2025

Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP)

August 26, 2025

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

August 25, 2025

Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results

August 6, 2025

Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025

July 30, 2025

Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025

July 12, 2025

Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025

July 7, 2025

Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis

June 2, 2025

Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences

May 20, 2025

Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome

May 11, 2025

Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results

May 7, 2025

Amylyx Pharmaceuticals to Participate in Upcoming May Investor Conferences

May 6, 2025

Amylyx Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025

April 30, 2025

Amylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia

April 29, 2025

Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis

April 8, 2025

Amylyx Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

April 1, 2025

Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

March 3, 2025

Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences

February 24, 2025

Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025

February 23, 2025

Amylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 9, 2025

Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis

January 20, 2025

Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock

January 9, 2025

Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer

January 5, 2025

Calls in 2025

Decks in 2025